Noradrenergic and serotonergic function in posttraumatic stress disorder

Archives of General Psychiatry

Volumn 54, Issue 8, 1997, Pages 749-758

  Southwick, Steven M ^a,b   Krystal, John H ^a,b   Bremner, J Douglas ^a,b   Morgan III, C A ^a,b   Nicolaou, Andreas L ^a   Nagy, Linda M ^a,b   Johnson, David R ^a,b   Heninger, George R ^a,b   Charney, Dennis S ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; YOHIMBINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR; BINDING AFFINITY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; PSYCHOTRAUMA; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

EID: 0030810755     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830200083012     Document Type: Article

References (106)

1. Tsuda A, Tanaka M. Differential changes in noradrenaline turnover in specific regions of rat brain produced by controllable and uncontrollable shocks. Behav Neurosci. 1985;99:802-817.
2. Tsuda A, Tanaka M, Ida Y, Tsujimaru S, Ushijima I, Nagasaki N. Effects of pre-shock experience on enhancement of rat brain noradrenaline turnover induced by psychological stress. Pharmacol Biochem Behav. 1986;24:115-119.
3. Stone EA. Accumulation and metabolism of norepinephrine in rat hypothalamus after exhaustive stress. J Neurochem. 1973;21:589-601.
4. Tanaka M, Kohno Y, Nakagawa R, Ida Y, Takeda S, Nagasaki N, Noda Y. Regional characteristics of stress-induced increases in brain noradrenaline release in rats. Pharmacol Biochem Behav. 1983;19:543-547.
5. Tanaks M, Kohno Y, Nagagawa R, Ida Y, Takeda S, Nagasaki N. Time-related differences in noradrenergic turnover in rat brain regions by stress. Pharmacol Biochem Behav. 1982;16:315-319.
6. Redmond DE Jr. Studies of the nucleus locus-coeruleus in monkeys and hypotheses for neuropsychopharmacology. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987: 967-975.
7. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats, I: acutely presented stressful and nonstressful stimuli. J Neurosci. 1987;7:2837-2843.
8. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus coeruleus: new evidence for anatomical and physiological specificity. Physiol Rev. 1983;63:844-914.
9. Levine ES, Litto WJ, Jacobs BL. Activity of cat locus coeruleus noradrenergic neurons during the defense reaction. Brain Res. 1990;531:189-195.
10. Aston-Jones G, Bloom FE. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1981;1:876-886.
11. Grant SJ, Aston-Jones G, Redmond DJ. Responses of primate locus coeruleus neurons to simple and complex sensory stimuli. Brain Res Bull. 1988;21:402-410.
12. Aston-Jones G, Valentino R, Van Blockstaele EJ. Locus coeruleus, stress, and PTSD: neurobiological and clinical parallels. In: Murburg M, ed. Catecholamine Function in PTSD: Emerging Concepts. Washington, DC: American Psychiatric Press; 1994:17-62.
13. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev. 1981;63:844-914.
14. Segal M, Bloom FE. The action of norepinephrine in the rat hippocampus, IV: the effects of locus coeruleus stimulation on evoked hippocampal unit activity. Brain Res. 1976;107:513-525.
15. Waterhouse BD, Moises HC, Woodward DJ. Noradrenergic modulation of somatosensory cortical neuronal responses to iontophoretically applied putative neurotransmitters. Exp Neurol. 1980;69:30-49.
16. McGaugh JI. Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu Rev Neurosci. 1989;2:255-287.
17. McGaugh JL. Significance and remembrance: the role of neuromodulatory systems. Psychol Sci. 1990;1:15-25.
18. Pitman RK. Posttraumatic stress disorder, hormones, and memory. Biol Psychiatry. 1989;26:221-223.
19. Squire LR. Mechanisms of memory. Science. 1986;232:1612-1619.
20. Devauges V, Sara SL. Memory retrieval enhancement by locus coeruleus stimulation: evidence for mediation by beta-receptors. Behav Brain Res. 1991;43: 93-97.
21. Sara SJ, Devauges V. Idazoxan, an alpha-2 antagonist, facilitates memory retrieval in the rat. Behav Neurol Biol. 1989;51:401-411.
22. LeDoux JE, Romanski L, Xagoraris A. Indelibility of subcortical emotional memories. J Cogn Neurosci. 1969;1:238-243.
23. Reiser M. Memory in Mind and Brain: What Dream Imaging Reveals. New York, NY: Basic Books Inc Publishers; 1991:2.
24. Cahil L, Prins B, Weber M, McGaugh S. B-Adrenergic activation and memory for emotional events. Nature. 1994;371:702-704.
25. Fraser F, Wilson EM. The sympathetic nervous system and the 'irritable heart of soldiers.' BMJ. 1918;2:27-29.
26. Dobbs D, Wilson WP. Observations on the persistence of neurosis. Dis Nerv Syst. 1960;21:40-46.
27. Blanchard EB, Kolb LC, Prins A, Gates S, McCoy GC. Changes in plasma norepinephrine to combat-related stimuli among Vietnam veterans with post traumatic stress disorder. J Nerv Ment Dis. 1991;179:371-373.
28. Malloy PF, Fairbank JA, Keane TM. Validation of a multimethod assessment of posttraumatic stress disorders in Vietnam veterans. J Consult Clin Psychol. 1983; 51:488-494.
29. Pallmeyer TP, Blanchard EB, Kolb LC. The psychophysiology of combat-induced posttraumatic stress disorder in Vietnam veterans. Behav Res Ther. 1986;24:645-652.
30. Pitman RK, Orr SP, Forgue DF, DeJong JB, Clairborn JM. Psychophysiologic assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. Arch Gen Psychiatry. 1987;44;970-975.
31. Orr SP. Psychophysiologic studies of post traumatic stress disorder. In: Giller EL, ed. Biological Assessment and Treatment of Post Traumatic Stress Disorder. Washington, DC: American Psychiatric Press; 1990:135-157.
32. Shalev AY, Orr SP, Pitman RK. Psychophysiologic assessment of traumatic imagery in Israeli civilian patients with posttraumatic stress disorders. Am J Psychiatry. 1993;150:620-624.
33. Pitman RK, Orr SP, Forgue DF, Altman B, deJong JB, Herz LR. Psychophysiologic responses to combat imagery of Vietnam veterans with posttraumatic stress disorder versus other anxiety disorders. J Abnorm Psychol. 1990;99: 49-54.
34. Kosten TR, Mason JW, Giller EL, Ostroff RB, Harkness L. Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroendocrinology. 1987;12:13-20.
35. Yehuda R, Southwick SM, Giller EL, Xiaowan MA, Mason JW. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis. 1992;180:321-325.
36. Perry BD, Giller EL, Southwick SM. Altered platelet alpha2 adrenergic binding sites in post-traumatic stress disorder. Am J Psychiatry. 1987;144:1511-1512.
37. Lerer B, Ebstein RP, Shestatsky M, Shemesh Z, Greenberg D. Cyclic AMP signal transduction in post-traumatic stress disorder. Am J Psychiatry. 1987;144: 1324-1327.
38. Blanchard EB, Hickling EJ, Taylor AC. The psychophysiology of motor vehicle accident related posttraumatic stress disorder. Biofeedback Self Regul. 1991; 16:449-458.
39. Southwick SM, Krystal JH, Morgan AC, Johnson D, Nagy L, Nicolaou A, Heninger GR, Charney DS. Abnormal noradrenergic function in post traumatic stress disorder. Arch Gen Psychiatry. 1993;50:266-274.
40. Starke K, Borowski E, Endo T. Preferential blockade of presynaptic alpha-adrenoreceptors by yohimbine. Eur J Pharmacol. 1975;34:385-388.
41. 2-adrenoreceptor. Pharmacol Rev. 1983;35:143-180.
42. Ruffolo RR Jr, Waddell JE, Yaden EL. Postsynaptic alpha adrenergic receptor subtypes differentiated by yohimbine in tissues from the rat: existence of alpha-2 adrenergic receptors in rat aorta. J Pharmacol Exp Ther. 1981;217:235-240.
43. Charney DS, Heninger GR, Breier A. Noradrenergic functions in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;42:751-763.
44. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987;144:1030-1036.
45. Gurguis GNM, Uhde IW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology. 1990;15:217-224.
46. Dunn AJ. Changes in plasma and brain tryptophan and brain serotonin and 5-hydroxyindoleacetic acid after footshock stress. Life Sci. 1989;42:1847-1853.
47. Morgan WW, Rudden PK, Pfeil KA. Effect of immobilization stress on serotonin content and turnover in regions of the rat brain. Life Sci. 1975;17:143-150.
48. Shimizu N, Take S, Hori T, Oomura Y. In vivo measurement of hypothalamic serotonin release by intracerebral microdialysis: significant enhancement by immobilization stress in rats. Brain Res Bull. 1992;28:727-734.
49. Tanaka M, Kohno Y, Nakagawa R, Nishikawa T, Tsuda A, Nagasaki N. Immobilization stress increases serotonin turnover in the extended brain regions in the rat. Kurume Med J. 1983;30:35-43.
50. 1C receptor activation in rats. Psychopharmacology. 1993;110:140-144.
51. Wright IK, Ismail H, Upton N, Marsden CA. Effect of isolation rearing on 5-HT agonist-induced responses in the rat. Psychopharmacology. 1991;105:259-263.
52. Kawahara H, Yoshida M, Yokoo H, Nishi M, Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett. 1993;162:81-84.
53. Arora RC, Fitchner CG, O'Connor F. Paroxetine binding in the blood platelets of posttraumatic stress disordered patients. Life Sci. 1993;53:919-928.
54. McDougle C, Southwick SM, Rorbaugh R, Charney DS, St James RJ. An open trial of fluoxetine in the treatment of post traumatic stress disorder. J Clin Psychopharmacol. 1991;1:325-327.
55. Nagy LM, Morgan CA, Southwick SM, Charney DS. Open prospective trial of fluoxetine for post traumatic stress disorder. J Clin Psychopharmacol. 1993; 13:107-113.
56. Davidson JRT, Ross S, Newman E. Fluoxetine in posttraumatic stress disorder. J Trauma Stress. 1991;4:419-423.
57. Shay J. Fluoxetine reduces explosiveness and elevates mood in Vietnam combat vets with PTSD. J Trauma Stress. 1992;5:97-102.
58. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry. 1994;55:517-522.
59. Brown GL, Linnoila ML. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry. 1990;51:31-41.
60. Stanley M, Stanley B. Postmortem evidence for serotonin's role in suicide. J Clin Psychiatry. 1990;51:22-28.
61. Wolf WA, Kuhn DM. The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int. 1991;19:39-44.
62. 1 recognition sites. J Recept Res. 1988;8:59-81.
63. Hamik A, Peroutka SJ. 1-(m-chlorophenyl) piperazine interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989;25:569-575.
64. 3 serotonin receptors, results of a structure-affinity study. Eur J Pharmacol. 1989;168:387-392.
65. 1B receptor ligands exist? Arch Pharmacol. 1989;339:675-683.
66. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine: receptor subtype. J Biol Chem. 1993;268:18200-18204.
67. 2 receptors in interneurons. Synapse. 1991;9:208-218.
68. 1C) receptors. J Pharmacol Exp Ther. 1987;242:552-557.
69. 2 activated interneuron. Brain Res. 1990;506:62-69.
70. 3H]-5-HT from human perfused platelets. Br J Clin Pharmacol. 1993;35:473-478.
71. Ireland SJ, Tyers MB. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rabbit isolated vagus nerve. Br J Pharmacol. 1987; 90:229-238.
72. 3 receptors. Life Sci. 1991;50:599-605.
73. 1 recognition sites. J Recept Signal Transduct Res. 1988;8:59-81.
74. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry. 1991;30:973-984.
75. Asnis GM, Wetzler S, Sanderson WC, Kahn RS, van Praag HM. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects. Psychiatry Res. 1992;43:65-76.
76. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Res. 1991;37:25-34.
77. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety, II: effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology. 1987;92:14-24.
78. Barr LC, Goodman WK, Price LH, McDougle CJ, Charney DS. The serotonic hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry. 1992;53(suppl):17-28.
79. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR. Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992;49:21-28.
80. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. 1991;36:1-17.
81. Barr LC, Goodman WK, Price LH. The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol. 1993;2:79-82.
82. Hollander E, Cohen LJ, DeCaria C, Saoud JB, Stein DJ, Cooper TB, Islam NN, Liebowitz MR, Klein DF. Timing of neuroendocrine responses and effect of a m-CPP and fenfluramine plasma levels in OCD. Biol Psychiatry. 1993;34:407-413.
83. Charney DS, Goodman WK, Price LH, Woods SW, Rasmusson SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy patients. Arch Gen Psychiatry. 1988;45:177-185.
84. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger Gr, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry. 1993;50:624-635.
85. Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL. Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients: initial experience with a serotonin agonist. Biol Psychiatry. 1990;28:588-594.
86. Anand A, Charney DS, Delgado PL, McDougle CJ, Heninger GR, Price LH. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry. 1994;151:1626-1630.
87. Overstreet DH, Rezvani AH, Janowsky DS. Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism. Biol Psychiatry. 1992;32:919-936.
88. Krystal JH, Webb E, Kranzler H, et al. Serotonergic and noradrenergic dysregulation in alcoholism: m-CPP and yohimbine effects in recently detoxified alcoholics and healthy subjects. Am J Psychiatry. 1996;153:83-92.
89. Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51:898-911.
90. Krystal JH, Webb E, Cooney NL, Kranzler HR, Southwick SM, Heninger GH, Charney DS. Serotonergic and noradrenergic dysregulation on alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry. 1996;153:83-92.
91. Benkelfat C, Murphy DL, Hill JL, George DT, Nutt D, Linnoila M. Ethanol-like properties of serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48:383.
92. Spitzer RL, Williams JBW. Structured clinical interview for DSM-III-R. New York, NY: Biometrics Research Department, NY State Psychiatric Institute; 1985.
93. Keane TM, Caddell JM, Taylor KL. Mississippi scale for combat-related post-traumatic stress disorder: three studies in reliability and validity. J Consult Clin Psychol. 1988;56:85-90.
94. Bremner JD, Ng CK, Staib L, Markey J, Duncan J, Zubal G, Krystal JH, Mazza S, Rich D, Southwick SM, Capelli S, Seibyl JP, Dey H, Soufer R, Charney DS, Innis RB. PET measurement of cerebral metabolism following a noradrenergic challenge in patients with posttraumatic stress disorder and in healthy subjects. J Nucl Med. 1993;3334:205-206.
95. Charney DS, Woods SW, Price LH, Goodman WK, Glazer WM, Heninger GR. Noradrenergic dysregulation in panic disorder. In: Ballenger JC, ed. Neurobiology of Panic Disorder. New York, NY: Wiley Liss; 1990:91-105.
96. Redmond DE Jr. New and old evidence for the involvement of a brain norepinephrine system in anxiety. In: Fann WE, ed. The Phenomenology and Treatment of Anxiety. New York, NY: Plenum Publishing Corp; 1979:153-203.
97. Rainey JM, Aleem A, Ortiz A, Yeragani V, Pohl R, Berchau R. A laboratory procedure for the induction of flashbacks. Am J Psychiatry. 1987;144:1317-1319.
98. Friedman MJ. Towards rational pharmacotherapy for post traumatic stress disorder. Am J Psychiatry. 1988;145:281-285.
99. Friedman MJ. Biological approaches to the diagnosis and treatment of post traumatic stress disorder. J Traum Stress. 1991;4:67-81.
100. Southwick SM, Yehuda R, Giller E, Charney DS. The effects of antidepressants in the treatment of post traumatic stress disorder: a quantitative review. In: Murburg M, ed. Catecholamine Function in Post-Traumatic Stress Disorder: Emerging Concepts. Washington, DC; American Psychiatric Press; 1994:293-305.
101. 2 binding affinity. Eur J Pharmacol. 1986;94:213-216.
102. 1 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 1988;94:213-216.
103. 2 receptors in rat brain. Neuropsychopharmacology. 1990;3:137-148.
104. Winter JC, Rabin RA. Yohimbine as a serotonergic agent: evidence for receptor binding and drug discrimination. J Pharmacol Exp Ther. 1992;263:682-689.
105. 2 Adrenergic receptor sensitivity in depression: the plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch Gen Psychiatry. 1988;45:718-726.
106. Southwick SM, Krystal JH, Johnson DR, Charney DS. Neurobiology of post traumatic stress disorder. In: Tasman A, Riba MG, eds. Review of Psychiatry. Washington, DC: American Psychiatric Press; 1992;11:347-370.